Melissa Selby
Primary Care · Roswell, GANPI 1437543261
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 37.1% of the total. Reporting peaked in 2021 at $1,436 and has fallen 69.9% since, to $432 in 2025.
Across 240 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$666
- Lilly USA, LLC$508
- Pfizer$172
- Biohaven Pharmaceuticals, Inc.$124
- AstraZeneca$114
- plus $853 from 16 others
What the payments were for
- Food & beverage$3,874100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 89 | $1,437 |
| Novo Nordisk | 54 | $666 |
| Lilly USA, LLC | 30 | $508 |
| Pfizer | 9 | $172 |
| Biohaven Pharmaceuticals, Inc. | 6 | $124 |
| AstraZeneca | 7 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $111 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $94 |
| IBSA Pharma Inc. | 4 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $84 |
| Exact Sciences | 4 | $70 |
| Eisai Inc. | 5 | $70 |
| Daiichi Sankyo Inc. | 3 | $60 |
| GSK | 3 | $53 |
| Amgen | 3 | $53 |
| Astellas Pharma US Inc | 2 | $40 |
| Merck | 2 | $37 |
| Esperion Therapeutics, Inc. | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Linus Health, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$124
How this compares
$3,874 in reported general payments places this provider in the 85th percentile of 235 primary care providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fenofibrate | 17 | $7,254 |
| Liothyronine Sodium | 12 | $1,434 |
| Losartan Potassium | 14 | $213 |
| Rosuvastatin Calcium | 16 | $179 |
| Levothyroxine Sodium | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Other primary care in Roswell
- Keela WeeksRoswell$3K
- Pamela TurkDouglas$15K
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
- Zanetta BryantNewnan$11K
- Hannah CummingsSuwanee$9K
- Michelle LadewigGainesville$7K
- Lucia OcanoviciuCanton$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.